Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

China pushes liver proteomics

Nature Biotechnology volume 22, page 136 (2004)Cite this article

Access through your institution
Buy or subscribe

Diseases of the liver are widespread in China. For example, China has over 180 million hepatits sufferers—more than half of the 350 million people affected worldwide. In order to address this serious health issue, the Chinese government launched a three-year pilot phase to build the infrastructure of the HLPP. If the project leads to progress for the diagnosis and treatment of liver diseases, the government will allocate another RMB 2 billion ($241.5 million) to the HLPP between 2006 and 2010.

The HLPP pilot phase consists of three parts: the study of protein expression profiles in the human liver, the study of protein-protein interactions in the human liver and the creation of an antibody bank. The latter could be a great asset to the biotechnology industry. Although approximately 10,000 antibodies are currently available from commercial sources globally, they are costly and many are not fully characterized. “This is why we are combining several leading domestic and international institutes to develop a huge database of antibodies to meet the demand of the HLPP,” says Qi-Hong Sun, chair of the HLPP antibody banking subcommittee.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Beijing

    Hepeng Jia

  2. Additional reporting by Sabine Louët, London

    Sabine Louët

Authors
  1. Hepeng Jia
    View author publications

    Search author on:PubMed Google Scholar

  2. Sabine Louët
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jia, H., Louët, S. China pushes liver proteomics. Nat Biotechnol 22, 136 (2004). https://doi.org/10.1038/nbt0204-136

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0204-136

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing